Predicting dopamine D2 receptor occupancy from plasma levels of antipsychotic drugs: A systematic review and pooled analysis

Journal of Clinical Psychopharmacology

Volumn 31, Issue 3, 2011, Pages 318-325

  Uchida, Hiroyuki ^a,b   Takeuchi, Hiroyoshi ^a   Graff Guerrero, Ariel ^b,c   Suzuki, Takefumi ^b,c   Watanabe, Koichiro ^a   Mamo, David C ^b,c  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

antipsychotic; dopamine; dopamine D2 receptor; positron emission tomography; schizophrenia

Indexed keywords

CLOZAPINE; DOPAMINE 2 RECEPTOR; FALLYPRIDE F 18; HALOPERIDOL; ISOREMOXIPRIDE; OLANZAPINE; RACLOPRIDE C 11; RADIOLIGAND; RISPERIDONE; UNCLASSIFIED DRUG; ZIPRASIDONE;

ARTICLE; BINDING SITE; DRUG BLOOD LEVEL; EMBASE; HUMAN; MEDLINE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SYSTEMATIC REVIEW;

ANTIPSYCHOTIC AGENTS; BRAIN; HUMANS; MODELS, BIOLOGICAL; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, DOPAMINE D2;

EID: 79955640309     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e318218d339     Document Type: Article

References (45)

1. Uchida H, Suzuki T, Mamo DC, et al. Effects of age and age of onset on prescribed antipsychotic dose in schizophrenia spectrum disorders: a survey of 1,418 patients in Japan. Am J Geriatr Psychiatry. 2008; 16:584-593.
2. Kapur S, Mamo D. Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27:1081-1090. (Pubitemid 37464954)
3. Farde L, Nyberg S, Oxenstierna G, et al. Positron emission tomography studies on D2 and 5-HT2 receptor binding in risperidone-treated schizophrenic patients. J Clin Psychopharmacol. 1995;15:19S-23S.
4. Kapur S, Zipursky R, Jones C, et al. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry. 2000;157:514-520. (Pubitemid 30191189)
5. Farde L, Nordstrom AL, Wiesel FA, et al. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry. 1992;49:538-544.
6. Mamo D, Kapur S, Keshavan M, et al. D2 receptor occupancy of olanzapine pamoate depot using positron emission tomography: an open-label study in patients with schizophrenia. Neuropsychopharmacology. 2008;33:298-304. (Pubitemid 350243350)
7. Mamo D, Kapur S, Shammi CM, et al. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am J Psychiatry. 2004;161:818-825. (Pubitemid 38625334)
8. Reardon GT, Rifkin A, Schwartz A, et al. Changing patterns of neuroleptic dosage over a decade. Am J Psychiatry. 1989;146:726-729. (Pubitemid 19149582)
9. Iyo M, Itoh T, Yamasaki T, et al. D2 receptor occupancy and plasma concentration of antipsychotics. Biol Psychiatry. 1990;28:1067-1070.
10. Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry. 1999;156:286-293. (Pubitemid 29077120)
11. Remington G, Mamo D, Labelle A, et al. A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone. Am J Psychiatry. 2006;163:396-401. (Pubitemid 44469380)
12. Uchida H, Kapur S, Mulsant BH, et al. Sensitivity of older patients to antipsychotic motor side effects: a PET study examining potential mechanisms. Am J Geriatr Psychiatry. 2009;17:255-263.
13. Uchida H, Pollock BG, Bies RR, et al. Predicting age-specific dosing of antipsychotics. Clin Pharmacol Ther. 2009;86:360-362.
14. Fitzgerald PB, Kapur S, Remington G, et al. Predicting haloperidol occupancy of central dopamine D2 receptors from plasma levels. Psychopharmacology. 2000;149:1-5. (Pubitemid 30187359)
15. Uchida H, Kapur S, Mulsant BH, et al. Sensitivity of older patients to antipsychotic motor side effects: a PET study examining potential mechanisms. Am J Geriatr Psychiatry. 2009;17:255-263.
16. Uchida H, Mamo DC, Kapur S, et al. Monthly administration of long-acting injectable risperidone and striatal dopamine D2 receptor occupancy for the management of schizophrenia. J Clin Psychiatry. 2008;69:1281-1286.
17. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm. 1981;9:503-512.
18. Yasuno F, Suhara T, Okubo Y, et al. Dose relationship of limbic-cortical D2-dopamine receptor occupancy with risperidone. Psychopharmacology (Berl). 2001;154:112-114. (Pubitemid 32186522)
19. Xiberas X, Martinot JL, Mallet L, et al. Extrastriatal and striatal D(2) dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia. Br J Psychiatry. 2001;179:503-508. (Pubitemid 34031674)
20. Gefvert O, Eriksson B, Persson P, et al. Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia. Int J Neuropsychopharmacol. 2005;8:27-36. (Pubitemid 40388811)
21. Arakawa R, Ito H, Takano A, et al. Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia. Psychopharmacology (Berl). 2008;197:229-235.
22. Catafau AM, Suarez M, Bullich S, et al. Within-subject comparison of striatal D2 receptor occupancy measurements using [123I]IBZM SPECT and [11C]Raclopride PET. Neuroimage. 2009;46:447-458.
23. Graff-Guerrero A, Mamo D, Shammi CM, et al. The effect of antipsychotics on the high-affinity state of D2 and D3 receptors: a positron emission tomography study With [11C]-(+)-PHNO. Arch Gen Psychiatry. 2009;66:606-615.
24. Nordstrom AL, Farde L, Nyberg S, et al. D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. Am J Psychiatry. 1995;152:1444-1449.
25. Farde L, Suhara T, Nyberg S, et al. A PET-study of [11C]FLB 457 binding to extrastriatal D2-dopamine receptors in healthy subjects and antipsychotic drug-treated patients. Psychopharmacology (Berl). 1997;133:396-404. (Pubitemid 27462815)
26. Kapur S, Roy P, Daskalakis J, et al. Increased dopamine d(2) receptor occupancy and elevated prolactin level associated with addition of haloperidol to clozapine. Am J Psychiatry. 2001;158:311-314. (Pubitemid 32116532)
27. Talvik M, Nordstrom AL, Nyberg S, et al. No support for regional selectivity in clozapine-treated patients: a PET study with [(11)C] raclopride and [(11)C]FLB 457. Am J Psychiatry. 2001;158:926-930. (Pubitemid 32547623)
28. Grunder G, Landvogt C, Vernaleken I, et al. The striatal and extrastriatal D2/D3 receptor-binding profile of clozapine in patients with schizophrenia. Neuropsychopharmacology. 2006;31:1027-1035.
29. Coppens HJ, Slooff CJ, Paans AM, et al. High central D2-dopamine receptor occupancy as assessed with positron emission tomography in medicated but therapy-resistant schizophrenic patients. Biol Psychiatry. 1991;29:629-634.
30. Karbe H, Wienhard K, Hamacher K, et al. Positron emission tomography with (18F)methylspiperone demonstrates D2 dopamine receptor binding differences of clozapine and haloperidol. J Neural Transm Gen Sect. 1991;86:163-173.
31. Kapur S, Zipursky R, Roy P, et al. The relationship between D2 receptor occupancy and plasma levels on low dose oral haloperidol: a PET study. Psychopharmacology (Berl). 1997;131:148-152. (Pubitemid 27261602)
32. Reimold M, Solbach C, Noda S, et al. Occupancy of dopamine D(1), D (2) and serotonin (2A) receptors in schizophrenic patients treated with flupentixol in comparison with risperidone and haloperidol. Psychopharmacology (Berl). 2007;190:241-249. (Pubitemid 46011184)
33. Vernaleken I, Fellows C, Janouschek H, et al. Striatal and extrastriatal D2/D3-receptor-binding properties of ziprasidone: a positron emission tomography study with [18F]Fallypride and [11C]raclopride (D2/D3-receptor occupancy of ziprasidone). J Clin Psychopharmacol. 2008;28:608-617.
34. Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. NeuroImage. 1996;4:153-158.
35. Uchida H, Kapur S, Pollock BG, et al. Optimal dosing of antipsychotic drugs in older patients with schizophrenia: PET investigations. Int J Neuropsychopharm. 2008;11(suppl 1):136.
36. Uchida H, Takeuchi H, Graff-Guerrero A, et al. Dopamine D2 receptor occupancy and clinical effects: a systematic review and pooled analysis. J Clin Psychopharmacology. [In press] .
37. Uchida H, Mamo DC, Mulsant BH, et al. Increased antipsychotic sensitivity in elderly patients: evidence and mechanisms. J Clin Psychiatry. 2009;70:397-405.
38. Zhou SF, Di YM, Chan E, et al. Clinical pharmacogenetics and potential application in personalized medicine. Curr Drug Metab. 2008;9:738-784.
39. Teh LK, Lee WL, Amir J, et al. Single step PCR for detection of allelic variation of MDR1 gene (P-glycoprotein) among three ethnic groups in Malaysia. J Clin Pharm Ther. 2007;32:313-319. (Pubitemid 46699519)
40. Mamo DC, Uchida H, Vitcu I, et al. Quetiapine extended-release versus immediate-release formulation: a positron emission tomography study. J Clin Psychiatry. 2008;69:81-86. (Pubitemid 351282000)
41. Ng W, Uchida H, Ismail Z, et al. Clozapine exposure and the impact of smoking and gender: a population pharmacokinetic study. Thert Drug Monit. 2009;31:360-366.
42. Yokoi F, Grunder G, Biziere K, et al. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride. Neuropsychopharmacology. 2002;27:248-259. (Pubitemid 34692591)
43. Kegeles LS, Slifstein M, Frankle WG, et al. Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride. Neuropsychopharmacology. 2008;33:3111-3125.
44. Mamo D, Graff A, Mizrahi R, et al. Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study. Am J Psychiatry. 2007;164: 1411-1417. (Pubitemid 47461142)
45. Grunder G, Fellows C, Janouschek H, et al. Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F]fallypride PET study. Am J Psychiatry. 2008;165:988-995.